98%
921
2 minutes
20
N-terminal-pro-brain natriuretic peptide (NT-pro BNP) is secreted by cardiomyocytes in cases of cardiac structure disorder and volume overload. However, the relationship between NT-pro BNP level and body fluid status in dialysis patients with reduced cardiac ejection function (EF) is uncertain. Therefore, we aimed to investigate this relationship. We enrolled patients who had been receiving hemodialysis for >3 months. Blood sample, transthoracic echocardiographic, and bioimpedance spectroscopy measurements were performed during a midweek non-dialysis day. The predictive value of NT-pro BNP in hemodialysis patients with volume overload was analyzed. A total of 129 hemodialysis patients (74 men and 55 women; mean age: 59.4 ± 13.0 years) were recruited. The average hemodialysis duration was 55.5 (23.9-93.4) months, the NT-pro BNP level was 4992 (2,033-15,807) pg/mL, and the value of overhydration was 2.68 ± 0.19 (-1.9 to 12.2) L. The NT-pro BNP level was independently correlated with overhydration in both the LVEF ≥ 60% (β = 0.236, = 0.044) and LVEF <60% (β = 0.516, = 0.032) groups, even after adjustments for potentially confounding variables. In receiver operating characteristic curves of NT-pro BNP for predicting volume overload, the area under the curve was 0.783 [95% CI (0.688-0.879), < 0.001) and 0.788 [95% CI (0.586-0.989), < 0.001] in the LVEF ≥ 60% and LVEF < 60% groups, respectively. NT-pro BNP is a predictive factor for volume overload in hemodialysis patients with or without EF declines.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937607 | PMC |
http://dx.doi.org/10.3389/fcvm.2021.646402 | DOI Listing |
Blood
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.
View Article and Find Full Text PDFHeart Lung
September 2025
Department of Cardiology, School of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. Electronic address:
Background: Acute heart failure with reduced ejection fraction (AHF) remains a leading cause of ED visits, hospitalizations, and in-hospital mortality.
Objectives: To evaluate the prognostic utility of the Scottish Inflammatory Prognostic Score (SIPS) in patients with AHF.
Methods: This retrospective study analyzed 508 patients admitted with AHF between November 2022 and November 2024.
Int J Cardiol Heart Vasc
October 2025
School of Wushu, Wuhan Sports University, Wuhan 430079, China.
The systematic -analysis was conducted to evaluate the clinical efficacy of Traditional Chinese Exercises (TCE) in the rehabilitation of patients with chronic heart failure (CHF). The findings provide evidence-based support for the implementation of non-pharmacological interventions in the management of CHF. A systematic search of PubMed, Web of Science, Cochrane Library, and Embase (up to November 2024) identified RCTs evaluating Traditional Chinese Exercise (TCE) for chronic heart failure rehabilitation.
View Article and Find Full Text PDFIntroduction: The study aims to investigate associations between markers of atrial cardiopathy and cognitive function trajectories in adults without prior AF.
Methods: The study included 4,486 participants from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Markers of atrial cardiopathy included atrial premature complexes and N-Terminal pro-Brain Natriuretic Peptide (NT pro-BNP).
Cardiooncology
September 2025
Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.
Background: SGLT2i exerts several cardiometabolic benefits in heart failure with reduced and preserved ejection fraction through the systemic reduction of insulin, visceral fat, chemokines and growth factors involved in cardiovascular diseases. Anthracyclines are considered the principal culprit drugs behind chemotherapy-induced cardiotoxicity. The pathognomonic manifestation of anthracycline-induced cardiotoxicity is a hypokinetic cardiomyopathy progressively leading to heart failure.
View Article and Find Full Text PDF